Oligodendroglioma clinical trials

The registry lists 414 studies for Oligodendroglioma across more than 10 countries. 32 are recruiting or about to start. 23 of them are mainly about Oligodendroglioma (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10.

Get an email when these change. Save the Oligodendroglioma studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 258
Terminated: 63
Recruiting: 25
Status unknown: 24
Withdrawn: 17
Active, not recruiting: 17

Phase

Phase 1: 193
Phase 2: 162
Phase 3: 24
Early Phase 1: 8
Phase 4: 2

Where

United States: 339
Canada: 35
United Kingdom: 20
Netherlands: 19
France: 19
Germany: 18

Who runs them

National Cancer Institute (NCI) (57) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (22) · Duke University (21) · Pediatric Brain Tumor Consortium (14) · City of Hope Medical Center (12) · Wake Forest University Health Sciences (11) · Jonsson Comprehensive Cancer Center (10) · Children's Oncology Group (10)

What is being tested here

Drugs under test in Oligodendroglioma studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Safusidenib	4	2	4
Temozolomide	3	7	62
G 207	1	0	2
Oncolytic HSV-1 G207	1	0	2
Cetuximab	1	0	2
Abexinostat	1	0	1
Mirdametinib	1	0	1
Olutasidenib	1	0	1
Eflornithine	1	0	1
Retifanlimab	1	0	1

Drug classes tested here Alkylating agents 3 open · Immune checkpoint inhibitors 2 open · HDAC inhibitors 1 open · Tyrosine kinase inhibitors (TKIs) 35 · Antimitotic agents 17

Coming up

9phase 3 studies under way

11studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Dec 2026Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma · Phase 3 · Eastern Cooperative Oncology Group
Nov 2026Pediatric Long-Term Follow-up and Rollover Study · Novartis Pharmaceuticals
Dec 2026Adaptive Radiotherapy and MRIs Based on Patients With Newly Diagnosed High-Grade Glioma · Columbia University
Dec 2026Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas · M.D. Anderson Cancer Center
Jan 2027A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2 · Dana-Farber Cancer Institute
Mar 2027Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms · Jazz Pharmaceuticals
Jun 2027All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma · Stephen Bagley, MD, MSCE
Jul 2027Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain Tumors · Memorial Sloan Kettering Cancer Center
Jul 2027A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma · University of Nebraska
Oct 2027Phase II Elderly/Frail Pts With Newly Diagnosed or Recurrent Malignant Glioma Treated With Cesium-131 GammaTile® · University of California, Irvine

Who these studies take

Of the 25 Oligodendroglioma studies recruiting now, 16 (64%) set no upper age limit and 7 (28%) stop at 75 or younger. 5 (20%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (4%) take healthy volunteers.

Recruiting studies that take each age, of 25
Age	Women	Men
10	3 (12%)	3 (12%)
18	23 (92%)	23 (92%)
30	21 (84%)	21 (84%)
40	20 (80%)	20 (80%)
50	20 (80%)	20 (80%)
65	19 (76%)	19 (76%)
75	18 (72%)	18 (72%)
85	17 (68%)	17 (68%)

Across all 414 studies, recruiting or not: 27% stop at 75 or younger and 22% at 65; 27% take children; <1% are for women only and <1% for men only; 2% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Oligodendroglioma studies take

Of 43 phase 1 interventional studies under Oligodendroglioma, half reached primary completion within 44 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 1	44 mo35–70 · 43 studies	—	44 mo35–92 · 36 studies
Phase 2	47 mo39–61 · 28 studies	—	—

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 13, 2026.

Started recruiting2

Living Well With Brain Cancer: A Group-Based Intervention to Promote Whole-Person Well-BeingNov 3, 2026NCT07628647
Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive DiseaseOct 20, 2026NCT07703436

Newly registered1

A Study of SRN-101 Gene Therapy in Adults With Recurrent High-Grade Glioma (ALERT-1)Oct 28, 2026NCT07902037

Studies

Recruiting first, then most recently updated. Showing 50 of 414. Browse all 414 → or search them.